PT - JOURNAL ARTICLE AU - Chong, Ka Chun AU - Cheng, Wei AU - Zhao, Shi AU - Ling, Feng AU - Mohammad, Kirran N. AU - Wang, Maggie Haitian AU - Zee, Benny Chung Ying AU - Wei, Lei AU - Xiong, Xi AU - Liu, Hengyan AU - Wang, Jingxuan AU - Chen, Enfu TI - Transmissibility of coronavirus disease 2019 (COVID-19) in Chinese cities with different transmission dynamics of imported cases AID - 10.1101/2020.03.15.20036541 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.15.20036541 4099 - http://medrxiv.org/content/early/2020/03/18/2020.03.15.20036541.short 4100 - http://medrxiv.org/content/early/2020/03/18/2020.03.15.20036541.full AB - Background Monitoring the time-varying reproduction number (Rt) of the disease is useful in determining whether there is sustained transmission in a population. In this study, we examined Rt of COVID-19 and compared its transmissibility between different intervention periods in Hangzhou and Shenzhen.Methods Daily aggregated counts of confirmed imported and local cases between January 1, 2020 and March 13, 2020 were analysed. A likelihood function was constructed to estimate Rt, accounting for imported cases.Results Although Hangzhou had fewer number of cases than Shenzhen, Shenzhen had higher proportion of imported cases than Hangzhou (83% vs 29%). Since the epidemic of COVID-19 in Shenzhen was dominated by imported cases, Rt was kept below unity through time. On the contrary, Rt was greater than unity in Hangzhou from 16 January to 7 February due to the surge in local cases. Credits to the Wuhan lockdown and outbreak response measures following the local lockdown, Rt decreased steadily and dropped below unity in mid-February.Conclusion The lockdown measures and local outbreak responses helped reduce the potential of local transmission in Hangzhou and Shenzhen. Meanwhile, cities with similar epidemic trend could have different transmission dynamics given the variation in imported cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by National Natural Science Foundation of China (31871340, 71974165). The funder has no role in the study design, in the collection, analysis and interpretation of data.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were downloaded from the official websites and they were publicly available.